Weiss Lawrence T. - 16 Jul 2025 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role: SVP, Chief Legal Officer
Signature: /s/ Lawrence Weiss
Issuer symbol: ANGO
Transactions as of: 16 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 18 Jul 2025, 18:06:25 UTC
Previous filing: 04 Dec 2024
Next filing: 22 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Weiss Lawrence T	SVP, Chief Legal Officer	14 PLAZA DRIVE, LATHAM	/s/ Lawrence Weiss	18 Jul 2025	0001930293

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANGO	Common Stock	Award	$0	+30,900	+59%	$0.000000	83,597	16 Jul 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANGO	Performance Right	Award	$0	+30,900		$0.000000	30,900	16 Jul 2025	Common Stock	30,900		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The acquisition of 30,900 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 30,900 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.
F2	Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Content

The acquisition of 30,900 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 30,900 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.

Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.